FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes

Eli Lilly & Company announced an the FDA advisory committee has voted against the label expansion of its SGLT-2 inhibitor Jardiance (empagliflozin 2.5 mg) as an adjunct to insulin for adults with type I diabetes